FDA CVM GFI #264 Standardized Medicated Feed Assay Limits

标准简介

CVM GFI #264 Standardized Medicated Feed Assay Limits[附网盘链接]是FDA于不久前发布的FDA标准,适用于United States。

标准截图

CVM GFI #264 Standardized Medicated Feed Assay Limits[附网盘链接]
CVM GFI #264 Standardized Medicated Feed Assay Limits[附网盘链接](截图)

 

标准文档说明

标准文档类型为CVM GFI #264 Standardized Medicated Feed Assay Limits[附网盘链接]高清PDF版本(文字版),标准文档内可进行搜索,可以复制原文,可粘贴。

标准部分原文

Draft — Not for Implementation Standardized Medicated Feed Assay Limits Draft Guidance for Industry This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. I. Introduction CVM establishes assay limits for drugs in medicated feeds (i.e., Type B and Type C medicated feeds) as part of the approval process for Type A medicated articles. The term “assay limits” refers to how much the measured amount of drug can deviate from the labeled amount of drug. The assay limits for Type B and Type C medicated feeds are specified as a range and published in 21 CFR §558.4(d). When a medicated feed assay value falls within this range using a validated method accepted by CVM, it indicates that the measured drug level in medicated feed is consistent with the labeled drug level. The assay limits are not intended to permit a feed manufacturer to add more or less than the labeled amount of drug to the medicated feed. Assay limits are used pre-approval to ensure that medicated feeds in Target Animal Safety (TAS), Effectiveness (EFF), Chemistry, Manufacturing, and Controls (CMC), Bioequivalence (BE), and Human Food Safety (HFS) residue chemistry studies contain the appropriate amount of drug, and post-approval for compliance and customer service purposes. This guidance recommends a standardized set of assay limits for medicated feeds. Standardized medicated feed assay limits allow predictability in the review process as sponsors can determine early in the drug development process what assay limits they should expect to meet for medicated feeds used in TAS, EFF, CMC, and HFS residue chemistry studies. The implementation of standardized medicated feed assay limits does not lower or otherwise change the current standards for safety and effectiveness and does not change the expectation regarding medicated feed assay methods, medicated feed assay method validation, and method transfer studies (see Guidance for Industry (GFI) #135, “Validation of Analytical Procedures for Type C 1

Medicated Feeds,” GFI #136, “Protocols for the Conduct of Method Transfer Studies for Type 2

C Medicated Feed Assay Methods,” and GFI #137, “Analytical Methods Description for Type 3

C Medicated Feeds” ). CVM will not require any additional medicated feed studies beyond those already required in the CMC technical section due to the implementation of standardized 1

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-135-validation-analytical-

procedures-type-c-medicated-feeds 2

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-136-protocols-conduct-

method-transfer-studies-type-c-medicated-feed-assay-methods 3

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-137-analytical-methods-

description-type-c-medicated-feeds

网盘链接

百度网盘:https://pan.baidu.com/s/1XlLOs1sXGP1i_tMiODqfnw
提取码:kx6x

【温馨提示】大资料ISO是提供信息发布的专业信息类网站,所有内容均由用户发布,不代表本站观点,本站亦不存储所涉及的文件及资料。如有【免费资料】以及【付费资料】,请用户根据自己的需求,自行判断是否需要获取。如有交易诈骗、内容侵权可发送邮件至kf@dzl100.com,我们审查后若发现情况属实,会立即对相关内容进行删除处理。

加载用时:36.1272 毫秒

相关评论

相关文章